Qiagen N.V. $QGEN Shares Sold by Generali Asset Management SPA SGR

Key Points

• Generali Asset Management SPA SGR reduced its stake in Qiagen N.V. by 49.5%, selling 33,290 shares in the second quarter, and now holds $1,633,000 worth of shares.
• Analyst ratings for Qiagen show mixed responses, with Bank of America raising its target price to $53.00 and UBS Group adjusting it to $50.00; the stock has an overall consensus rating of "Hold."
• Qiagen reported $0.60 earnings per share, meeting estimates, with a revenue increase of 7.7% year-over-year, reaching $533.54 million in its latest earnings announcement.

Generali Asset Management SPA SGR cut its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 49.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,968 shares of the company's stock after selling 33,290 shares during the quarter. Generali Asset Management SPA SGR's holdings in Qiagen were worth $1,633,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of QGEN. GAMMA Investing LLC grew its stake in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock valued at $716,000 after buying an additional 395 shares in the last quarter. Blue Trust Inc. grew its stake in Qiagen by 30.5% during the 1st quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock worth $543,000 after purchasing an additional 3,157 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Qiagen by 4.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after purchasing an additional 109,481 shares in the last quarter. Finally, Envestnet Asset Management Inc. acquired a new position in Qiagen during the 1st quarter worth $13,463,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on QGEN. UBS Group boosted their target price on Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Weiss Ratings reissued a "hold (c+)" rating on shares of Qiagen in a research note on Wednesday, October 8th. Bank of America boosted their target price on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Cowen reaffirmed a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Finally, Barclays set a $53.00 price target on Qiagen and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Three analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Qiagen currently has a consensus rating of "Hold" and a consensus target price of $49.69.

Qiagen Stock Up 0.3%

Shares of NYSE QGEN opened at $48.29 on Friday. The stock has a market cap of $10.73 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.66. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The business has a 50-day moving average price of $47.00 and a 200 day moving average price of $45.77.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same period in the prior year, the firm earned $0.55 EPS. The business's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.